EyePoint, Inc., incorporated in Delaware on March 19, 2008, is a clinical-stage biopharmaceutical company dedicated to developing and commercializing innovative therapies to help improve the lives of patients with severe retinal diseases. The Company utilizes its proprietary biodegradable Durasert E technology for continuous intraocular drug delivery, addressing the challenges posed by frequent intravitreal injections. Its lead product candidate, DURAVYU, is an investigational therapy for the treatment of vascular endothelial growth factor-mediated retinal diseases.
